FDA Clears Tandem Mobi as First Tubeless AID Pump With 7-Day Wear
TNDM sits 43% above its 52-week low of $12.26.
Summary
Tandem won FDA clearance to sell Tandem Mobi as a tubeless automated insulin delivery system with up to seven days of infusion set wear — the company says it is the first and only such product, and the only insulin pump cleared for both tubed and tubeless wear options. Existing Mobi pumps are already compatible, so current in-warranty users need no new hardware; only the new cartridge and infusion set are required, and Tandem will contact eligible in-warranty customers with details on how to access the new sets and cartridges when they become available. That lowers the adoption barrier and gives Tandem a differentiated claim against tubeless competitors in a market where it is trying to defend share. The catch is timing: full U.S. launch is planned for the first half of 2027, and the sets will be sold exclusively through the pharmacy channel, where Tandem estimates coverage for only about 50% of insured lives today, though it expects pharmacy coverage for Mobi to expand ahead of the launch and throughout 2027. Shares rose 14.48% to $20.05 on the clearance. This lands a week after Q3 sales of $283.7 million (up 14%) and the formal 2026 U.S. revenue target of roughly $730 million to $745 million, so it supports the growth story without changing near-term numbers. Watch pharmacy coverage expansion through 2027 — that, not the clearance itself, determines how much revenue the tubeless option actually adds.
Updated with a Benzinga report · What changed
Updates
· Benzinga — Tandem Diabetes Care shares rose 14.48% to $20.05 following the FDA clearance of Tandem Mobi as a tubeless automated insulin delivery system.
- Mobi is the only insulin pump cleared for both tubed and tubeless wear options.
- Tandem will contact eligible in-warranty customers with details on how to access the new sets and cartridges when they become available.
- Tandem expects pharmacy coverage for Mobi to expand ahead of the launch and throughout 2027.
At the time of this announcement, TNDM was trading at $17.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $12.26 to $29.65. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.